Oricell Therapeutics secured more than $110 million in a pre-IPO financing to advance its lead solid-tumor CAR-T program targeting GPC3, a protein enriched on liver cancer cells. The company said the new capital will expand its global footprint and support registrational studies for Ori-C101 in advanced hepatocellular carcinoma. Ori-C101 is an autologous CAR-T designed for GPC3-positive tumors. Oricell previously completed investigator-initiated work and a registrational Phase 1 study across dose levels; in the company’s described small cohort, the highest dose achieved an objective response and nine patients reached disease control. The round also reflects investor confidence in next-generation approaches for solid tumors, where antigen heterogeneity and an immunosuppressive tumor microenvironment complicate CAR-T efficacy. Oricell’s broader pipeline includes multiple other oncology programs and additional modalities such as next-generation and in vivo CAR-T concepts. The financing strengthens Oricell’s position as it moves closer to pivotal trial milestones while signaling that solid-tumor CAR-T developers are continuing to fund through the pre-IPO window despite tougher capital conditions for other segments.